Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin
Antimicrobial Agents and Chemotherapy · 2023
DOI: 10.1128/aac.00431-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2023. Verfasst von Allan Kengo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa. Hauptthemen laut MEDLINE: Antibiotics, Antitubercular, Tuberculosis, HIV Infections, Anti-HIV Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: FIC NIH HHS, NIAID NIH HHS, EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership.
Abstract (Originalsprache)
We characterized the pharmacokinetics of standard- and high-dose rifampicin in Ugandan adults with tuberculosis and HIV taking dolutegravir- or efavirenz-based antiretroviral therapy. A liver model with saturable hepatic extraction adequately described the data, and the increase in exposure between high and standard doses was 4.7-fold. This was lower than what previous reports of dose-exposure nonlinearity would predict and was ascribed to 38% lower bioavailability of the rifampicin-only top-up formulation compared to the fixed-dose combination.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Clinical Pharmacology, University of Cape Town , Cape Town, South Africa.
- Infectious Disease Institute, College of Health Sciences, Makerere University , Kampala, Uganda.
- Department of Pharmacy, Radboud university medical center , Nijmegen, the Netherlands.
- Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Centre , Nashville, Tennessee, USA.
- Division of Infection and Global Health, School of Medicine, University of St. Andrews , Scotland, United Kingdom.
ORCID-Profile: Allan Kengo
Förderung
- FIC NIH HHS
- NIAID NIH HHS
- EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership
- HHS | NIH | NIH Office of the Director
- Scottish Funding Council
Zitieren
APA
Kengo, A., Gausi, K., Nabisere, R., Musaazi, J., Buzibye, A., Omali, D., Aarnoutse, R., Lamorde, M., Dooley, K. E., Sloan, D. J., Sekaggya-Wiltshire, C., & Denti, P. (2023). Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00431-23
Vancouver
Kengo A, Gausi K, Nabisere R, Musaazi J, Buzibye A, Omali D, et al. Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin. Antimicrobial Agents and Chemotherapy. 2023. doi:10.1128/aac.00431-23
BibTeX
@article{Kengo2023,
author = {Kengo, Allan and Gausi, Kamunkhwala and Nabisere, Ruth and Musaazi, Joseph and Buzibye, Allan and Omali, Denis and Aarnoutse, Rob and Lamorde, Mohammed and Dooley, Kelly E and Sloan, Derek James and Sekaggya-Wiltshire, Christine and Denti, Paolo},
title = {Unexpectedly low drug exposures among Ugandan patients with TB and HIV receiving high-dose rifampicin},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2023},
doi = {10.1128/aac.00431-23}
}
EUVIMED